{"success":true,"data":{"pressRelease":{"id":"17957","rtpr_id":"nACSCNwPPa","ticker":"GOSS","exchange":"NASDAQ","all_tickers":["GOSS"],"title":"Pomerantz LLP Informs Shareholders of Securities Class Action Against Gossamer Bio, Inc.  – GOSS","author":"ACCESSWIRE","published_at":"2026-05-02T22:00:00.898Z","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 2,\n2026 / Pomerantz LLP announces that a class action lawsuit has been filed\nagainst Gossamer Bio, Inc. (\"Gossamer\" or the \"Company\") (NASDAQ:GOSS).  \nSuch investors are advised to contact Danielle Peyton at newaction@pomlaw.com\nor 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by\ne-mail are encouraged to include their mailing address, telephone number, and\nthe number of shares purchased.\n\nThe class action concerns whether Gossamer and certain of its officers and/or\ndirectors have engaged in securities fraud or other unlawful business\npractices.\n\nYou have until June 1, 2026, to ask the Court to appoint you as Lead Plaintiff\nfor the class if you purchased or otherwise acquired Gossamer securities\nduring the Class Period. A copy of the Complaint can be obtained at\nwww.pomerantzlaw.com.        \n\n[Click here for information about joining the class action]\n(https://pomlaw.com/learn-more-form?company=GOSS)\n\nOn February 23, 2026, Gossamer issued a press release and hosted a call to\nannounce topline results for its Phase 3 PROSERA study evaluating seralutinib\nfor the treatment of pulmonary arterial hypertension, which failed to meet the\nprimary endpoint of improved six-minute walk distance at Week 24, with a +13.3\nmeter placebo-adjusted gain (p-0.0320) failing to meet the required 0.025\nalpha threshold. Gossamer attributed this miss to patients at Latin American\nsites performing particularly well on placebo due to enrollment of a heavily\ntreated lower-risk population.\n\nOn this news, Gossamer's stock price fell $1.71 per share, or 80.13%, to close\nat $0.42 per share on February 23, 2026.\n\nPomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris,\nand Tel Aviv, is acknowledged as one of the premier firms in the areas of\ncorporate, securities, and antitrust class litigation. Founded by the late\nAbraham L. Pomerantz, known as the dean of the class action bar, Pomerantz\npioneered the field of securities class actions. Today, more than 85 years\nlater, Pomerantz continues in the tradition he established, fighting for the\nrights of the victims of securities fraud, breaches of fiduciary duty, and\ncorporate misconduct. The Firm has recovered numerous multimillion-dollar\ndamages awards on behalf of class members. See www.pomlaw.com.\n\nAttorney advertising.  Prior results do not guarantee similar outcomes.\n\nSOURCE: Pomerantz LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/pomerantz-llp-informs-shareholders-of-securities-class-action-ag-1154727)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSCNwPPa","title":"Pomerantz LLP Informs Shareholders of Securities Class Action Against Gossamer Bio, Inc.  – GOSS","author":"ACCESSWIRE","ticker":"GOSS","created":"2026-05-02T22:00:00.898Z","tickers":["GOSS"],"exchange":"NASDAQ","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 2,\n2026 / Pomerantz LLP announces that a class action lawsuit has been filed\nagainst Gossamer Bio, Inc. (\"Gossamer\" or the \"Company\") (NASDAQ:GOSS).  \nSuch investors are advised to contact Danielle Peyton at newaction@pomlaw.com\nor 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by\ne-mail are encouraged to include their mailing address, telephone number, and\nthe number of shares purchased.\n\nThe class action concerns whether Gossamer and certain of its officers and/or\ndirectors have engaged in securities fraud or other unlawful business\npractices.\n\nYou have until June 1, 2026, to ask the Court to appoint you as Lead Plaintiff\nfor the class if you purchased or otherwise acquired Gossamer securities\nduring the Class Period. A copy of the Complaint can be obtained at\nwww.pomerantzlaw.com.        \n\n[Click here for information about joining the class action]\n(https://pomlaw.com/learn-more-form?company=GOSS)\n\nOn February 23, 2026, Gossamer issued a press release and hosted a call to\nannounce topline results for its Phase 3 PROSERA study evaluating seralutinib\nfor the treatment of pulmonary arterial hypertension, which failed to meet the\nprimary endpoint of improved six-minute walk distance at Week 24, with a +13.3\nmeter placebo-adjusted gain (p-0.0320) failing to meet the required 0.025\nalpha threshold. Gossamer attributed this miss to patients at Latin American\nsites performing particularly well on placebo due to enrollment of a heavily\ntreated lower-risk population.\n\nOn this news, Gossamer's stock price fell $1.71 per share, or 80.13%, to close\nat $0.42 per share on February 23, 2026.\n\nPomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris,\nand Tel Aviv, is acknowledged as one of the premier firms in the areas of\ncorporate, securities, and antitrust class litigation. Founded by the late\nAbraham L. Pomerantz, known as the dean of the class action bar, Pomerantz\npioneered the field of securities class actions. Today, more than 85 years\nlater, Pomerantz continues in the tradition he established, fighting for the\nrights of the victims of securities fraud, breaches of fiduciary duty, and\ncorporate misconduct. The Firm has recovered numerous multimillion-dollar\ndamages awards on behalf of class members. See www.pomlaw.com.\n\nAttorney advertising.  Prior results do not guarantee similar outcomes.\n\nSOURCE: Pomerantz LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/pomerantz-llp-informs-shareholders-of-securities-class-action-ag-1154727)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-05-02T22:00:00.938621489Z","server_sent_at_ms":1777759200938},"received_at":"2026-05-02T22:00:01.001Z","source_url":"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/pomerantz-llp-informs-shareholders-of-securities-class-action-ag-1154727"},"analysis":{"id":"13096","press_release_id":"17957","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Pomerantz LLP announced a class action lawsuit against Gossamer Bio, alleging securities fraud related to the company's February 23 disclosure regarding its Phase 3 PROSERA study.\n\nThe lawsuit centers on the topline results where seralutinib failed to meet its primary endpoint in pulmonary arterial hypertension patients, triggering an 80% stock drop.\n\nInvestors have until June 1, 2026, to seek appointment as lead plaintiff.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{"drugName":"seralutinib","phaseOfTrial":"Phase 3"},"quotedText":"","namedEntities":{"people":[{"name":"Danielle Peyton","role":"Contact"}],"products":["seralutinib"],"companies":[{"name":"Gossamer Bio, Inc.","ticker":"GOSS"},{"name":"Pomerantz LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$1.71 per share","context":"stock price decline on February 23, 2026"},{"amount":"$0.42 per share","context":"stock closing price on February 23, 2026"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Pomerantz LLP. No new disclosure from the issuer; no certified class, no settlement. Boilerplate lead-plaintiff-deadline reminder."},"tickerRelevance":{"others":[],"primary":"GOSS"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Pomerantz LLP announced a class action lawsuit against Gossamer Bio, alleging securities fraud related to the company's February 23 disclosure regarding its Phase 3 PROSERA study.\n\nThe lawsuit centers on the topline results where seralutinib failed to meet its primary endpoint in pulmonary arterial hypertension patients, triggering an 80% stock drop.\n\nInvestors have until June 1, 2026, to seek appointment as lead plaintiff.","key_figures":{"drugName":"seralutinib","phaseOfTrial":"Phase 3"},"named_entities":{"people":[{"name":"Danielle Peyton","role":"Contact"}],"products":["seralutinib"],"companies":[{"name":"Gossamer Bio, Inc.","ticker":"GOSS"},{"name":"Pomerantz LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$1.71 per share","context":"stock price decline on February 23, 2026"},{"amount":"$0.42 per share","context":"stock closing price on February 23, 2026"}]},"model_name":"glm-4.7","prompt_hash":"sha256:a2703c5a1b5285fe","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-05-02T22:00:45.911Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":29798,"modelName":"glm-4.7"}}